Accessibility Menu
Lifecore Biomedical Stock Quote

Lifecore Biomedical (NASDAQ: LFCR)

$6.77
(0.1%)
+0.01
Price as of October 22, 2025, 3:56 p.m. ET

KEY DATA POINTS

Current Price
$6.77
Daily Change
(0.1%) +$0.01
Day's Range
$6.75 - $6.92
Previous Close
$6.77
Open
$6.81
Beta
1.21
Volume
5,619
Average Volume
157,783
Market Cap
253.3M
Market Cap / Employee
$6.76M
52wk Range
$4.76 - $8.85
Revenue
-
Gross Margin
0.31%
Dividend Yield
N/A
EPS
-$1.3
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Lifecore Biomedical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
LFCR+28.76%-32.4%-7.53%-47%
S&P+15.06%+95.03%+14.29%+934%

Lifecore Biomedical Company Info

Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$36.44M-3.8%
Gross Profit$13.98M-19.0%
Gross Margin38.37%-7.2%
Market Cap$250.66M40.5%
Market Cap / Employee$0.62M0.0%
Employees406-22.5%
Net Income-$1.15M83.8%
EBITDA$4.81M12.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$8.27M-2.3%
Accounts Receivable$43.67M40.2%
Inventory32.3-19.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$128.34M2.3%
Short Term Debt$3.82M-22.1%

Ratios

Q2 2025YOY Change
Return On Assets-15.09%-18.6%
Return On Invested Capital-13.63%-2.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$3.25M-47.0%
Operating Free Cash Flow$5.35M-39.0%

Valuation

MetricQ2 2024Q3 2024YoY Change
Price to Earnings24.23100.67-
Price to Book11.83-58.1413.98112.46612.92%
Price to Sales1.441.921.591.9344.18%
Price to Tangible Book Value-19.79-10.40-82.05-15.81-40.06%
Enterprise Value to EBITDA-39.52853.52-1741.0487.0210.76%
Return on Equity17.3%-29.6%-83.6%-76.4%-464.38%
Total Debt$136.86M$131.34M$130.34M$132.17M1.39%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.